We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord

Ticker
REG1V.HE

Price
22.55
Stock movement down
-0.20 (-0.88%)
Company name
Revenio Group Corporation
Exchange
(HE
,
Currency
EUR
)
Sector
Healthcare >
Medical Devices
Markedsværdi
599.90M
Ent værdi
-
Pris/omsætning
5.50
Pris/bog
5.50
Udbytte afkast
-
Udbyttevækst
-
Vekst år
-
FCF-udbetaling
-
Efterfølgende P/E
32.43
Fremtidig P/E
23.31
PEG
-
EPS-vekst
14.55%
1 års afkast
-16.61%
3 års afkast
-
5 års afkast
-
10 års afkast
-
Senest opdateret: 2025-12-17

UDBYTTE

REG1V.HE betaler ikke udbytte

VÆRDIANSÆTTELSE

Værdiansættelsesforhold

Loading...
Værdiansættelsesforhold-data
Efterfølgende P/E32.43
Pris til OCF16.85
Pris til FCF14.52
Pris til EBITDA20.52
EV i forhold til EBITDA-

Værdiansættelse (salg/bogført værdi)

Loading...
Værdiansættelse (salg/bogført værdi)-data
Pris til omsætning5.50
Pris til egenkapital5.50
EV i forhold til salg-

ØKONOMI

Pr. aktie

Loading...
Data pr. aktie
Aktuelt antal aktier26.60M
EPS (TTM)-
FCF pr. aktie (TTM)-

Resultatopgørelse

Loading...
Resultatopgørelse-data
Omsætning (TTM)-
Bruttofortjeneste (TTM)-
Driftsindkomst (TTM)-
Nettoindkomst (TTM)-
EPS (TTM)-
EPS (1 år frem)0.97

Marginer

Loading...
Marginer-data
Bruttomargin (TTM)-
Driftsmargin (TTM)-
Fortjenstmargin (TTM)-

Balance

Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Balancedata
Kontanter0.00
Nettotilgodehavender17.20M
Omsætningsaktiver i alt41.80M
Goodwill62.80M
Immaterielle aktiver22.60M
Ejendomme, anlæg og udstyr0.00
Sum aktiver137.00M
Kreditor0.00
Kortfristet/nuværende langsigtet gæld0.00
Summen af kortfristede forpligtelser17.60M
Sum gæld28.00M
Aktionærernes egenkapital109.00M
Materielle nettoaktiver0.00

Likviditet

Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Kontantstrøm-data
Likviditet fra driften (TTM)-
Investeringsudgifter (TTM)-
Fri pengestrøm (TTM)-
Udbetalt udbytte (TTM)-

Finansiel indkomst

Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Data om finansiel indkomst
Egenkapitalafkast-
Afkast af aktiver-
Afkast af investeret kapital-
Kontant afkast af investeret kapital-

INFORMATION OM AKTIER

Aktiediagram

Loading...
Aktiekurs-data
Åbning22.75
Daglig høj22.75
Daglig lav22.20
Daglig volumen12K
Højeste gennem alle tider70.70
1 års analytiker estimat28.75
Beta1.36
EPS (TTM)-
Udbytte pr. aktie0.00
Ex-div dato11 Apr 2025
Næste dato for resultatpræsentation12 Feb 2026

Nedsidepotensial

Loading...
Nedsidepotensial-data
REG1V.HES&P500
Nuværende prisfald fra top notering-68.10%-2.58%
Højeste prisfald-69.52%-19.00%
Højeste efterår dato3 Dec 20258 Apr 2025
Gennemsnitlig fald fra toppen-62.74%-2.63%
Gennemsnitlig tid til nyt højdepunkt-6 days
Maks. tid til nyt højdepunkt299 days89 days
OPLYSNINGER OM VIRKSOMHEDEN
REG1V.HE (Revenio Group Corporation) company logo
Markedsværdi
599.90M
Markedsværdi kategori
Small-cap
Beskrivelse
Revenio Group Oyj, provides ophthalmological devices and software solutions for the diagnosis of glaucoma, macular degeneration, and diabetic retinopathy in Finland, the United States, and internationally. The company offers iCare IC100, ST500, and IC200 tonometers; iCare HOME2, a tonometer to measure eye pressure; iCare Probes that are accessories of iCare tonometer for measuring intraocular pressure (IOP); iCare TONOVET Pro, a tonometer designed for use in surgical or emergency settings; and iCare TONOVET Plus tonometer, which is used for measuring IOP on animal patients by general veterinary practitioners, veterinary ophthalmologists and other veterinary medical personnel. It also provides imaging devices comprising iCare EIDON, a device with confocal retinal imaging; iCare DRSplus, a device for pupil imaging; and iCare COMPASS, which provides fundus perimetry with true-color confocal retinal images. In addition, the company offers iCare ILLUME, a screening software that helps to detect the early signs of diabetic retinopathy, age-related macular degeneration, and glaucoma using artificial intelligence; iCare CLINIC cloud software to store long-term IOP data; and Oculo, an eye care software platform, which combines clinical communication, telehealth, remote patient monitoring and data analytics capabilities. Revenio Group Oyj was incorporated in 2001 and is based in Vantaa, Finland.
Personale
248
Investor relationer
-
SEC-indsendelser
Adm. direktør
Land
Finland
By
Aktietype
-
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRÆSENTATIONER
ArrangementerPræsentationer
Loading...
FORSTÅ FORRETNINGEN
Loading...
NYHEDER OM VIRKSOMHEDEN
Alle nyhederPressemeddelelser
As European markets show mixed returns, with the STOXX Europe 600 Index edging higher on hopes of interest rate cuts, investors are keenly analyzing opportunities in value stocks trading below their e...
11. december 2025
Revenio Group Oyj (HLSE:REG1V) posted a solid set of numbers, with earnings forecast to grow 17.4% per year and revenue projected to increase by 11.2% annually, both comfortably outpacing the Finnish ...
31. oktober 2025
The European stock market has recently experienced a notable upswing, with the pan-European STOXX Europe 600 Index reaching record levels amid a rally in technology stocks and expectations for lower U...
7. oktober 2025
The cider brand has added a high-contrast NaviLens QR code to its cans.
9. september 2025
BioReference health, JPMorgan Chase and an Italian fashion retailer are making the job cuts amid market uncertainty
9. september 2025
Temenos also the winner for Bank Deposit Transformation with Credem and listed in the 2025 IDC FinTech Rankings Top 25GRAND-LANCY, Switzerland, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Temenos (SIX: TEMN), ...
9. september 2025
The Management Board of Artea Bankas has approved changes to the management and organizational structure. The Management Board has received a notice from board member Mindaugas Rudys regarding his res...
9. september 2025
Novartis will acquire Tourmaline Bio for $48 per share, valuing the New York-based biopharmaceutical company at $1.4 billion on a fully diluted basis, the Swiss pharma giant said on Tuesday. Tourmali...
9. september 2025
As European markets experience tentative optimism due to potential trade agreements with the U.S., and the European Central Bank maintains a steady interest rate, investors are keenly observing opport...
29. juli 2025
Revenio Group Oyj (FRA:R0V) reports a robust first quarter with significant sales growth, strategic product launches, and plans to mitigate tariff impacts.
30. april 2025
Næste side